In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck is taking steps to suspend the availability of its cholesterol drug, Tredaptive tablets worldwide, following a recommendation from European regulators. Tredaptive (extended-release niacin ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

An acquisition by Merck was “hard to resist” given the company’s long history and expertise in drug development, experience ...

Belen Garijo took charge of German drug-to-semiconductor group Merck KGaA with the tailwind of the Covid pandemic, propelling the stock to an all-time high in 2021. Since then, the shares have ...

Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its ...

Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key drugs Gardasil and Winrevair. Merck's diversified pipeline includes promising oncology ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...